Dupixent Improved Moderate-To-Severe Asthma In Phase 3 Trials

Results showed Dupixent demonstrated improvement in multiple asthma endpoints in a broad population of patients with uncontrolled asthma, irrespective of minimum baseline eosinophil levels or other biomarkers of Type 2 inflammation